Drug intelligence / Profile preview

cadonilimab + mFOLFOX6

Development stage: Unknown
Lead developer: Kangfang Sainuo Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Cadonilimab (AK104) plus mFOLFOX6 is a combination therapy being evaluated for the neoadjuvant treatment of locally advanced rectal cancer (LARC). Cadonilimab is a humanized tetravalent IgG1 bispecific antibody developed by Akeso that simultaneously targets the immune checkpoints PD-1 (programmed cell death-1) and CTLA-4 (cytotoxic T-lymphocyte antigen-4). By blocking these pathways, it relieves immunosuppressive effects and reverses tumor-specific T cell exhaustion. mFOLFOX6 is a standard chemotherapy regimen consisting of oxaliplatin, leucovorin, and 5-fluorouracil. In clinical research led by investigator Wan He at Shenzhen People's Hospital, this combination is administered following short-course radiotherapy (SCRT) to improve the pathologic complete response (pCR) rate in patients with mismatch repair-proficient (pMMR) or microsatellite-stable (MSS) rectal cancer.

Brand names: Kaitanni
Other names: cadonilimab plus mFOLFOX6AK104 plus mFOLFOX6AK-104 plus mFOLFOX6AK 104 plus mFOLFOX6AK104 plusAK-104 plusAK 104 plus

Targets

PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on cadonilimab + mFOLFOX6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cadonilimab + mFOLFOX6.

Explore the full profile